Across
- 2. "BMS's trusted hardware partner powering the peripherals behind our digital workplace"
- 4. "BMS therapeutic area targeting the heart — home to Eliquis and next-gen pipeline assets"
- 9. "A next-generation CELMoD agent on the cusp of approval in 2025 — BMS's pipeline promise in hematology"
- 10. "The coagulation factor targeted by Milvexian — a novel node in the clotting cascade"
- 11. "BMS's breakthrough muscarinic therapy for adults living with this condition — the first new mechanism in decades"
- 13. "BMS's first-in-class erythroid maturation agent approved for anemia in MDS and beta-thalassemia"
- 16. "BMS's proprietary platform that modulates cereblon E3 ligase to degrade disease-causing proteins"
- 19. "The critical process of bringing an approved BMS medicine from launch to patients at scale"
- 20. "BMS's largest and most storied therapeutic area — fighting cancer on every front"
Down
- 1. "The serious mental illness that COBENFY treats via a first-in-class muscarinic mechanism"
- 3. "BMS's flagship PD-1 checkpoint inhibitor, a pioneer in cancer immunotherapy"
- 5. "BMS's internal digital program championed by our CTO to fast-track innovation and transformation"
- 6. "BMS's Chief Technology Officer, steering the company's digital and tech transformation"
- 7. "BMS's strategic focus on using technology and data to transform patient outcomes and care delivery"
- 8. "Surname of BMS's Chief Executive Officer, leading the company into its next chapter"
- 12. "BMS's oral TYK2 inhibitor — the first of its kind — approved for moderate-to-severe plaque psoriasis"
- 14. "The immune checkpoint receptor targeted by Opdivo to unleash T-cells against tumors"
- 15. "BMS therapeutic area dedicated to unlocking the brain — home to COBENFY and beyond"
- 17. "BMS's investigational FXIa inhibitor aiming to redefine anticoagulation with a safer profile"
- 18. "One of BMS's core values — a relentless drive to act quickly for patients who can't wait"